ImmunoGen has been granted a patent for antibodies and immunoconjugates targeting CD123 antigen for diagnosing and treating diseases like B-cell malignancies. The patent includes a specific formula for immunoconjugates. GlobalData’s report on ImmunoGen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ImmunoGen, Nanoparticle drug conjugates was a key innovation area identified from patents.
Immunoconjugates binding to cd123 antigen for treating diseases
A recently granted patent (Publication Number: US11897961B2) discloses an immunoconjugate with a specific formula, including an antibody or antigen-binding fragment with defined amino acid sequences. The immunoconjugate is characterized by the presence of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region with specific CDR sequences. Additionally, the patent outlines variations in the amino acid sequences of the heavy and light chain variable regions, providing detailed sequences for different configurations of the antibody or antigen-binding fragment.
Furthermore, the patent describes the immunoconjugate's composition, including specific peptide sequences containing 2 to 5 amino acid residues. The patent lists a variety of peptide options that can be used in the immunoconjugate, such as Gly-Gly-Gly, Ala-Val, Val-Cit, and many others. The patent also covers the representation of the immunoconjugate formula and the inclusion of a pharmaceutical composition comprising the immunoconjugate and a pharmaceutically acceptable carrier. Overall, the patent provides detailed information on the structure, composition, and pharmaceutical application of the immunoconjugate, offering valuable insights for researchers and professionals in the field.
To know more about GlobalData’s detailed insights on ImmunoGen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
